A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
A phase 1/2 trial of FL115+PD-1 in advanced solid tumours, run by Suzhou Forlong Biotechnology Co., Ltd, now recruiting.
Overview
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07131202 by Suzhou Forlong Biotechnology Co., Ltd, with 130 participants planned, started 2026-01-08 and due to reach its primary completion in 2026-12-05. Interventions recorded: FL115+PD-1.
Similar pages
not linked directly; found by shared links- TrialA Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
Shares Suzhou Forlong Biotechnology and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAuger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.